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Introduction
The Hitachi 705 analyser was evaluated for three months, in line
with the recommendations of the ’Sociedad Espafiola de
Quimica Clinica’ (SEQC) [1].
A 10-channel configuration was selected to suit the require-
ments ofthe emergency laboratory in which the instrument was
installed, and to represent different types of chemical determi-
nations. The analyses performed were alpha-amylase (AMYL),
creatin kinase (CK), creatin kinase isoenzyme MB (CK-MB),
alanine aminotransferase (ALT), aspartate aminotransferase
(AST), glucose (GLU), urea (UREA), creatinine (CREA), cal-
cium (CA), and protein (TP). (The electrolytes analyser assembly
was not available at the time of evaluation.) The aspects
evaluated included imprecision at three different levels; carry-
over; linearity; and relative accuracy when compared with the
laboratory’s routine analysers: an SMAC autoanalyser
(Technicon Instrument Corporation, Tarrytown, New York,
USA), and an ABA-100 (Abbott Laboratories, South Pasadena,
California, USA).
Materials and methods
The instrument
The Hitachi 705 is a compact, discrete, selective multianalyser
for clinical chemistry laboratories. The instrument is capable of
simultaneously performing up to 16 tests/sample, plus sodium,
potassium and chloride measurements, which are always made
together (with an optional accessory). The sample throughput is
180 tests/h, or 220 tests/h ifelectrolytes are included. The routine
procedure can be interrupted by stat samples at any time,
returning afterwards to the original sequence. Sodium, potass-
ium and chloride determinations are performed by ion-
selective permeable microelectrodes with dialytic cellulose
membranes for Na +, K +, and C1-. The analytical method for
biochemical determinations employs either endpoint or rate
assays with a single reagent or two reagents. An endpoint assay
has a maximum reaction time of 10 min, with the possibility ofa
sample blank correction. Kinetic assays may be performed
freely.
Routine sample, stat samples, standard solutions, a blank
solution and control sera are loaded on the sample disc. The
serum and reagent pipettes are driven by a stepper motor and
are supplied with a probe-washing device and a liquid-level
sensor. The sample probe aspirates the serum (from 5 to 20
and discharges it into each reaction cuvette on the reaction disc
and/or into the Na+, K+, C1- measuring vessel. (The sample
volume required for the electrolytes is 100#1.) The reagent
pipetting unit picks up the required volume ofreagent (from 100
to 500 #1) from its bottle in the refrigerated reagent store. The
reagent is heated in the pipettes to the specified incubation
temperature and is then discharged into the reaction cells
containing the serum samples. The incubation water-bath has a
temperature range of25-37C. The reaction disc, which holds 48
semidisposable reaction cuvettes, rotates so that each cuvette
crosses the optical path of the spectrophotometer (11 fixed
wavelengths between 340 and 700 nm); absorbance is measured
directly at two wavelengths.
Measurements are taken up to 31 times at 20 intervals over
a period of 10min after the addition of the first reagent. When
each sample has been measured, its reaction cuvette is
thoroughly washed. The washing unit includes a facility for
measuring the absorbance of the reaction cuvettes once they
have been refilled with distilled water. The value obtained is
stored and used as a reference value for the next measurement.
The analyser is controlled by a computer with which the
operator communicates by means of a keyboard, a visual-
display unit and a magnetic tape. Up to 40 analytical methods
can be programmed into the computer.
All analytical methods are open to variation and are stored
on tape. The functions of the microprocessor are many,
including selecting the requested test for each sample.
Concentration results are printed out after compensation for the
reaction cuvette absorbance, photometer drift and self blank,
and arithmetic operations on values obtained in a rate assay,
endpoint assay, single and double assay. It will automatically
establish a calibration curve for any parameter. It monitors the
average value, normal value range, standard deviation and
coefficient of variation for three types of control sera. It is
equipped with an alarm unit to warn the operator about
substrate exhaustion, reagent shortage, errors, and malfunc-
tions. In addition, it can be connected on line to an external
computer system.
Analytical methods and reagents
Alpha-amylase was assayed using a colorimetric test with
p-nitrophenyl-alpha-D-maltoheptoside as substrate [2].
Creatin kinase, alanine aminotransferase and aspartate
aminotransferase were measured by the optimized standard
methods recommended by the Deutsche Gessellschaft fiir
Klinische Chemie [3-6]. Creatin kinase isoenzyme MB was
measured using an immuno-inhibition assay test [7], and
creatinine by the Jafl’ kinetic method without deproteinization
[8]. The GOD-PAP method [9] was used for glucose. The
urease-GLDH assay [10] was adapted to analyse urea. The
colorimetric method with o-cresolphthalein complexone without
deproteinization [11] was used to measure calcium. Protein
assay was carried out by the Biuret method with sample blank
[12]. Analytical details are shown in table 1. The working
reagents, solutions and calibrators were supplied by Boehringer
Mannheim GmbH. The control sera used were Validate
(General Diagnostics), Sera Chem (Fisher Diagnostics),
Precinorm-U, Precipath-U, and CK-MB control (Boehringer
Mannheim GmbH).
Standardization
Standardization was normally undertaken at the start of each
day following the instructions in the instrument’s manual. The
reagent blanks were measured for all the parameters.
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Table 1. Details of methods used for measurements on the Hitachi 705.
(Where 21 =peak wavelength and ,2 =side band wavelength.)
Sample volume Total volume Analytical
(#1) (#1) method
Wavelength Temperature
(nm) (C)
Alpha-amylase 10 430 Kinetic
Creatin kinase 10 430 Kinetic
Creatin kinase-MB 15 405 Kinetic
Aspartate aminotransferase 20 440 Kinetic
Alanine aminotransferase 20 440 Kinetic
Glucose 5 505 End point
Urea 5 360 Fixed time
Creatinine 20 440 Kinetic
Calcium 10 410 End point
Protein 10 410 End point
415 660 30
340 376 30
340 376 30
340 376 30
340 376 30
600 546 30
340 376 30
505 57O 3O
600 660 30
340 376 30
Calibration curves were produced for glucose, creatinine,
calcium, protein, urea, and alpha-amylase, using Precinorm-U
as the calibrator (the Precinorm-U used as calibrator was
different from that used as the control). A factor, obtained after
several calibrator analyses, was applied to creatin kinase, creatin
kinase isoenzyme MB, alanine aminotransferase, and aspartate
aminotransferase determinations.
Imprecision
The within-day imprecision was evaluated by analysing control
sera at three different levels of concentration 30 times within a
single batch (within one calibration).
The day-to-day imprecision was determined using frozen
aliquots of control sera with three different levels of analyte
which were analysed each day for 30 working days.
Linearity
A serum with a high concentration ofthe analyte in question was
diluted with saline or with another serum containing a relatively
low level of that analyte; so mixtures with linearly-related
concentrations were obtained. These were used for linearity
studies.
Carry-over
The features of the instrument required studies of the possi-
bilities of contamination in the sample probe, reagent pipette,
and reaction cuvettes.
Sample probe carry-over
Control sera at three different levels of concentration (H high,
M medium, L low) were used for each analyte and processed
according to the SEQC’s recommendations (table 2). The
Snedecor F-test ( 0"05) was used to assess contamination
between samples of different concentrations for each analyte.
The variance of all the results was compared for each analyte at
each level with the variance ofthe results obtained from samples
not susceptible to carry-over.
Reagent pipette carry-over
To study reagent-to-reagent carry-over one analyte was alter-
nated with the others, as shown in the sequence for creatin
kinase:
AMYL/CK/CK/CK/CK-
MB/CK/AST/CK/ALT/CK/GLU/CK /
UREA/CK/CREA/CK/CA/CK/TP/CK.
4O
The coefficient of variation for the measurement of creatin
kinase under these circumstances was then calculated. Similar
sequences were then prepared for each analyte, using the same
control sera, and the corresponding coefficients of variation
were calculated.
Reaction cuvette carry-over
Cuvette contamination was assessed according to the protocol
ofKnedel [ 13]; this allows determination ofwhether one analyte
is affected by another when the same reaction cuvette is used.
After employing the sequence: AMYL/CK/CK-MB/AST/
ALT/GLU/UREA/CREA/CA/TP, the same 10 cuvettes are
used to assay only one ofthe analytes. The procedure is repeated
for each analyte, thus allowing calculation ofthe corresponding
coefficients of variation.
Relative accuracy
Glucose, urea, creatinine, calcium, and protein in sera from 110
patients were assayed by the Hitachi 705, and the results
obtained were compared with those from the SMAC analyser
using the same sera. The analytical procedures used by the
SMAC are described elsewhere [14].
Table 2. Sample sequence for measuring sample
carry-over according to the SEQC. (H, M, and L= high,
medium, and low concentration levels of analyte
respectively.)
H L* H* L*
H* L* L H
H* L* L* H*
H H H H*
L H* H* L
L* H* H* L*
M M M L*
M* M* M* L*
M* M* M* L*
L H L H
H L H H*
H* L* H* H*
L L* L M
L* H L* M*
L* H* L* M*
uncontaminated test levels.Table 3. Within-day imprecision at three concentrations.
N Mean CV
Alpha-amylase (U/I)
Creatin kinase (U/l)
Creatin kinase-MB (U/L)
Aspartate aminotransferase (U/l)
Alanine aminotransferase (U/l)
Glucose (mmol/1)
Urea (mmol/1)
Creatinine (#tool/l)
Calcium (mmol/1)
Protein (g/l)
30 40"0 4.3
30 264"3 1.0
30 714.7 1.6
30 33.3 2.9
30 81.7 1.6
30 257’0 0"6
30 13.8 8’8
30 39-0 3.2
30 111.7 1.4
30 12"8 3.2
30 36"5 1.4
30 134.0 0.4
30 19.5 2.6
30 52.4 0"9
30 126"0 0"5
30 3.2 1.6
30 4.9 1.6
30 12"9 0"5
30 3.7 0’8
30 7"0 1.0
30 14.0 0"6
30 65"6 2.9
30 92.9 2.3
30 302.0 0"9
30 1"6 0"9
30 2.4 0.7
30 3.1 0"5
30 39"9 0"9
30 59"7 1.1
30 80’4 0"9
Table 4.
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Day-to-day imprecision at three concentrations.
N Mean CV
Alpha-amylase (U/I) 30 54.1 4.2
30 282.3 1.4
30 1153.2 1.0
Creatin kinase (U/I) 30 51.0 5.2
30 70.9 4.4
30 340.5 3.8
Creatin kinase-MB (U/l) 30 14.3 8"9
30 33.9 4.0
30 111.1 3.3
Aspartate aminotransferase (U/l) 30 11.8 4.5
30 33.9 4.0
30 151.1 3.3
Alanine aminotransferase (U/l) 30 22.5 3.6
30 41.6 3.0
30 148.0 2.5
Glucose (mmol/1) 30 3.2 3.1
30 4.6 2.3
30 13.9 1.4
Urea (mmol/1) 30 3.8 2.9
30 4.7 2.5
30 16.5 2.2
Creatinine (ktmol/1) 30 61.6 4.0
30 80.4 2.3
30 555.0 1.6
Calcium (mmol/1) 30 1’6 2"0
30 2"4 1"4
30 3"1 1.3
Protein (g/l) 30 48.8 2.0
30 62.6 2.0
30 78.8 1.8
The alpha-amylase comparison was done with the ABA-100
analyser using 50 patient sera; the analytical reaction was the
same as the Hitachi 705’s.
Results and discussion
Imprecision
Within-day imprecision at each level studied is shown in table 3.
Day-to-day imprecision is given in table 4.
The results show a remarkably low coefficient ofvariation at
low, medium, and high levels of concentration for the analytes.
The disappointing imprecision obtained at the low level for
creatin kinase isoenzyme MB may be due at the very low
increment of absorbances produced by such low catalytic
concentrations.
Linearity
The linearity for each constituent was assessed by visual
inspection of the plot. Linearity for glucose and urea was up to
30mmol/1, alpha-amylase up to 745U/1, creatin kinase and
creatin kinase isoenzyme MB up to 1600U/I, aspartate and
alanine aminotransferase up to 1000U/l, creatinine up to
1000 #mol/1, calcium up to 4 mmol/1 and protein up to 100g/1.
Table 5. Sample probe carry-over for glucose.
Results (mmol/1)permutation
13"0 H 3"1 L* 13"1 H* 3"2 L*
13"1 H* 3"1 L* 3’2 L 13"0 H
13"1 H* 3"1 L* 3"2 L* 13"1 H*
13"1 H* 13"2 H 13"2 H 13"2 H*
3"2 L 13"2 H* 13"1 H* 3"3 L
3"1 L* 13"1 H* 13"3 H* 3"2 L*
5’1 M 5"1 M 5"2 M 3"1 L
5’0 M* 5’2 M* 5"1 M* 3"1 L*
5"0 M* 5"1 M* 5"2 M* 3"2 L*
3’ L 13"2 H 3" L 13"2 H
13"1 H 3"2 L 13"1 H 13"1 H*
13"1 H* 3"2 L* 13"2 H* 13"1 H*
3"1 L 3"2 L* 3"1 L 5"1 M
3"2 L* 13"1 H 3"3 L* 5"2 M*
3’1 L* 13"0 H* 3"1 L* 5"2 M*
* uncontaminated values.
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Table 6. Sample probe carry-over for glucose.
SD1 =standard deviation for all the glucose values (nl)
including the effects of contamination. SDz=standard
deviation of glucose values (n2) without the effects of
contamination.
Snedecor’s
Level nl n2 X SD1 SD2 value
High 24 15 13.1 0"073 0.070 1.10
Medium 12 8 5’ 12 0"075 0"088 1.37
Low 24 15 3" 16 0.070 0.072 1.04
Table 7. Coefficients ofvariationfrom reagent pipette and
from reaction cuvette carry-over studies compared with the
imprecision coefficients.
Reagent Reaction Within-day
pipette cuvette precision
cv Vo cv Vo cv Vo
Alpha-amylase 0"3
Creatin kinase 0.5
Creatin kinase-MB
Aspartate aminotransferase
Alanine aminotransferase 0.6
Glucose 0.4
Urea 0"6
Creatinine 1’0
Calcium 0.6
Protein 0"8
2.3 4.3
1.4 ,1.0
0.5 I’6
2.6
1"3
0.6
9"0
3.6
1.6
3.0
1.6
0.4
2.4
0"9
0.6
0"6
0.9
0"6
1"2
0.6
0.4
1.8
1.3
0"5
1,2
1.0
0.9
2.9
1"6
0.6
8.8
3.2
1.4
3.2
1-4
0.4
2"6
0"9
0"5
1-6
1.6
0"5
0.8
1.0
0.6
2.9
2.3
0.9
0.9
0.7
0.5
1.2 0.9
1.2 1.1
1.0 0.9
Carry-over
Sample probe carry-over
In no case was there any significant difference between the
compared variances. For each analyte at each ofthe three levels
the method was the same as the glucose case shown in tables 5
and 6.
Reagent pipette carry-over
The coefficients of variation obtained in the reagent pipette
carry-over were similar to those obtained in the imprecision
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Table 8. Reagent pipette carry-over for creatin kinase.
AMYL (U/l) 684.7
CK (U/l) 258
CK (U/l) 260
CK (U/l) 258
CK-MB (U/l) 111
CK (U/l) 257
AST (U/l) 130
CK (U/l) 257
ALT (U/l) 127
CK (U/l) 258
GLU (mmol/1) 12.2
CK (U/l) 260
UREA (mmol/1) 13.4
CK (U/l) 258
CREA (/mol/1) 298
CK (U/l) 257
CA (mmol/1) 3"0
CK (U/l) 258
TP (g/l) 80
CK (U/l) 260
riCK 11
=258
SD= 1"19
CV =0"46
Table 9. Reaction cuvette carry-over for alpha-amylase.
Cuvette First run Second run
AMYL (U/l) 684.7 AMYL 264.3
2 CK (U/l) 258 AMYL 264.3
3 CK-MB (U/l) 110 AMYL 264.3
4 AST (U/l) 130 AMYL 264"3
5 ALT (U/l) 128 AMYL 264.3
6 GLU (mmol/1) 12.0 AMYL 270.3
7 UREA (mmol/1) 13.4 AMYL 270-3
8 CREA (#mol/1) 297 AMYL 264.3
9 CA (mmol/l) 2.9 AMYL 270.3
10 TP (g/l) 79.6 AMYL 264.3
30.0
24.0
18 .0
12.0
.I
Ob
0 0
Figure 1. Regression line for glucose. Scales in mmol/1.
x=SMAC values (from comparison method), y=Hitachi
values.
study (table 7). The procedure followed for each analyte was as
the creatin kinase example (table 8). No appreciable carry-over
was detected.Table 10.
C. Ferr/ et al. Evaluation of the Hitachi 705 analyser
Regression study. (Where x =routine method; y= studied method.)
Pairs Range of Standard Standard Coefficient
compared values deviation deviation of Residual of
N compare& Slope of slope y-intercept y-intercept variance determination
Glucose
Urea
Creatinine
Calcium
Protein
Amylase
110 2’6-28"8 0"93 0"01 0"34 0"06 0"0683 0"9916
110 2"8-29"8 0"93 0"01 0"59 0"06 0"1094 0"9966
59 36-98 0"89 0"04 3"51 3"25 29"0534 0"8768
51 102-565 0"83 0.01 12"35 3"09 86"1424 0"9913
110 1"6-2"6 1"00 0"02 -0.04 0"04 0"0018 0’9621
110 41-80 1’04 0"02 1.64 1"43 2"7922 0"9538
50 30-594 0"98 0"01 0"96 3"75 250"8259 0"9910
594.0
475. 2
356.4
237 .5
118.8
e
.i
Figure 2. Regression linefor alpha-amylase. Scales in U/1.
x ABA-1 O0 values (from comparison method), y Hitachi
values.
Reaction cuvette carry-over
The coefficients of variation obtained in the reaction cuvette
carry-over study were similar to those obtained when .impre-
cision was investigated (table 7). The alpha-amylase example
(table 9) shows the procedure followed for each analyte. Again,
no appreciable carry-over was detected.
Relative accuracy
Relative accuracy was investigated by the linear regression
method [15] (table 10). Graphs showing the regression lines
between the Hitachi results and those obtained from the
Technicon SMAC and ABA-100 are shown for glucose(figure 1)
and for alpha-amylase (figure 2). Similar graphs were obtained
for the other analytes. Statistically, the regression lines show
neither a proportional nor a systematic error for calcium,
protein, and alpha-amylase, however, for glucose, urea, and
creatinine a proportional and a systematic error exist (table 10).
Conclusions
The Hitachi 705 analyser has proved to be a highly reliable and
precise instrument for measuring the analytes studied. The
coefficients of variation obtained are below those of clinical
significance, according to Barnett [16-1, and within the range
recommended by the SEQC.
The linearity of the methods is sufficiently broad to allow
measurements of pathological levels without the necessity of
diluting the sample except in extreme cases. Carry-over is
insignificant. However, the comparative study of the Hitachi
methodology with the SMAC and ABA-100 systems revealed
only a good relative accuracy for calcium and protein (SMAC)
and alpha-amylase (ABA-100). Calibration and programming
are not overcomplicated, although training and experience is
necessary, as with most automatic analytical systems. Only the
very simple maintenance procedures, on a daily, weekly and
monthly basis, are required.
The instrument can comfortably analyse 200-300 speci-
mens/day, as required in a medium-size laboratory. Emergency
samples may be given priority at any time.
The instrument, rather surprisingly, lacks a built-in sample-
identification system: this facility might be expected considering
the sophistication of the machine in other areas, i.e. the ease
with which analytical methods may be modified, its versatility in
accommodating kinetic tests, the elimination of priming before
starting analyses, the small reaction and sample volumes needed,
and the lack of requirement for commercial reagents.
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